Stock Ratings / Health Care / SSII / financials

BWAY (61) CERS (37) DCTH (57) NPCE (30) ⌘ Pro Terminal →

SS Innovations International Inc. (SSII) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.38 -2.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

SS Innovations International Inc. (SSII) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $477.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-8.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SSII)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SSII Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $5.9M

FY24

Rev $20.6M

FY25

Rev $42.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$42.5M	46%	-19.3%	-$12.1M	-$22.2M	-18.5%
FY 2024	$20.6M	40.9%	-80%	-$19.2M	-$10.2M	-45%
FY 2023	$5.9M	46%	-80%	-$20.9M	-$15.4M	-18.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SSII)

✓Walkthrough of SSII's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SSII // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.80%▼ DESCENDING CHANNEL

2026-10-30O $2.32H $2.50L $2.30C $2.38VOL 49.7K

RES: $3.77SUP: $2.11SMA50: $2.96SMA200: $3.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SSII Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SSII Butterfly Map → + Track SSII →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +105.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SSII today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SSII. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SSII today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SSII)

Health Care Rank #671 of 1016 ⚔️ BWAY vs SSII Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SSII vs. BWAY, CERS, DCTH, NPCE)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SS Innovations International Inc. (SSII) ranks #671 by composite RQD confidence (39/100, grade D-) and #463 by equity capitalization ($477.2M). Within this direct 5-issuer industry benchmark cohort, SSII leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. BWAY currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with SSII at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SSII ACTIVE SS Innovations International Inc.	D-	39/100	—	46.0%	-18.5%	-2.46%	$477.2M	Benchmark Subject
BWAY BrainsWay Ltd.	C-	61/100	—	—	—	+4.93%	$478.7M	/bway-vs-ssii →
CERS Cerus Corporation	D-	37/100	—	—	-15.5%	+0.83%	$491.7M	/cers-vs-ssii →
DCTH Delcath Systems Inc.	D+	57/100	—	86.2%	0.8%	-1.48%	$508.0M	/dcth-vs-ssii →
NPCE Neuropace Inc.	E	30/100	—	77.2%	-23.0%	+0.62%	$446.6M	/npce-vs-ssii →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001676163

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SS Innovations International Inc. (SSII) reported GAAP revenue of $42.5M (+105.7% vs. FY2024 revenue of $20.6M , and +623.1% cumulative change since FY2023) , GAAP net income of -$12.1M, operating cash flow of -$18.5M, and free cash flow of -$22.2M (-118.4% YoY). On the balance sheet, SSII closed FY2025 with $74.2M in total assets against $0 in total debt (Altman Z-Score: 7.47, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$42.5M	-$12.1M	-$18.5M	-$22.2M	$74.2M	—
FY2024 (FY)	2024-12-31	$20.6M	-$19.2M	-$9.5M	-$10.2M	$42.4M	—
FY2023 (FY)	2023-12-31	$5.9M	-$20.9M	-$15.4M	-$15.4M	—	—

3. SSII Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SSII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, SS Innovations International Inc. (NASDAQ: SSII) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $2.38 (-2.46% 1D, market cap $477.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SSII ranks #671 in composite RQD confidence.

How does SSII compare to BWAY and CERS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SSII carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 46.0%, and ROIC of -18.5%. By comparison, BWAY (BrainsWay Ltd.) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $478.7M) and CERS (Cerus Corporation) posts a D- grade (37/100 RQD, P/E N/A, ROIC -15.5%, cap $491.7M). Among the 5-stock peer group, SSII leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SSII?

Per SSII's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001676163), SS Innovations International Inc. generated $42.5M in revenue (+105.7% YoY), -$12.1M in net income, and -$22.2M in free cash flow against $74.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SSII trading relative to its 50-day, 200-day, and 52-week technical levels?

SSII last traded at $2.38 (-2.46% on volume of 95,164 shares), positioning the stock -19.59% below its 50-day simple moving average ($2.96) and -38.66% below its 200-day simple moving average ($3.88). Across its 52-week range of $2.20 to $8.21, SSII sits at the 3.0% percentile with a 14-day RSI of 35.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.08 to $2.68).